Skip to content

AHA/ACC/ADA/ASN 2026: cardiovascular–kidney–metabolic (CKM) syndrome

International AHA/ACC/ADA/ASN Current

2026 AHA/ACC/ADA/ASN Guideline for the Management of Cardiovascular-Kidney-Metabolic Syndrome

Circulation. 2026;154:e50–e158
DOI 10.1161/CIR.0000000000001453 · Summary checked against the source: 2026-11

Read or download the original

The first guideline for CKM syndrome: the links between obesity, diabetes, CKD and cardiovascular disease. It stages people from 0 to 4 and matches therapy to stage and to which conditions overlap.

At a glance

  1. Stage everyone by metabolic risk factors, eGFR (plus UACR from stage 2) and CVD. [1, B-NR · e58]
  2. Estimate risk with PREVENT (10-year CVD, ASCVD and HF, age 30–79; 30-year risk at 30–59). [1, B-NR · e67]
  3. Weight loss of at least 5–10% through lifestyle first. GLP-1-based therapy from stage 1 (BMI ≥27). [1, A · e75; 2a, A · e79]
  4. Type 2 diabetes with raised CV risk (PREVENT-CVD ≥7.5%): SGLT2i or GLP-1-based therapy, regardless of glucose. [1, A · e83]
  5. CKD: RASi (UACR ≥30) → SGLT2i (eGFR ≥20) → finerenone (T2D, UACR ≥30, eGFR ≥25) → GLP-1-based therapy (T2D, UACR ≥100). [e88]
  6. Pre-HF (stage 3): SGLT2i first if T2D or CKD. [1, B-NR · e93]
  7. Keep kidney-protective drugs going when eGFR falls below the starting threshold. [2a, B-R · e112]

Stages

Stage Definition
0 No risk factors: normal BMI and waist, glucose, BP and lipids; no CKD or CVD
1: Excess or dysfunctional adiposity BMI ≥25 (≥23 in Asians), waist ≥88/102 cm (women/men; ≥80/90 cm in Asians), or prediabetes (FPG 100–125 mg/dL, HbA1c 5.7–6.4%)
2: Metabolic risk factors or CKD Hypertension (≥130/80 or treated), TG ≥150, metabolic syndrome, type 2 diabetes, and/or moderate–high-risk CKD (KDIGO)
3: Subclinical CVD CAC ≥100 (or other subclinical atherosclerosis, low ABI); pre-HF (NT-proBNP ≥125, raised hs-troponin, or abnormal echo); or risk equivalents: very-high-risk CKD (G4–G5) or PREVENT-CVD ≥20%
4: Clinical CVD CHD, HF, stroke, PAD or AF with CKM risk factors. 4a no kidney failure; 4b kidney failure (eGFR <15 or dialysis)

Adapted from AHA/ACC/ADA/ASN 2026 Table 4 [e61]

Monitoring

Stage Lipids, glucose, eGFR BP Other
0 Every 5 years Yearly BMI and waist yearly (all stages)
1 Every 2–3 years Yearly
2 and above Yearly (lipids, glucose) Yearly eGFR and UACR yearly

Adapted from AHA/ACC/ADA/ASN 2026 longitudinal assessment recommendations [1, B-NR · e63]

  • Social determinants of health: screen everyone with a validated tool. [1, B-NR · e65]
  • Interdisciplinary care with a coordinator when ≥2 of diabetes, CKD and CVD coexist. [1, B-R · e70]
  • PREVENT-HF ≥5%: check natriuretic peptides or troponin for pre-HF. [2a, B-NR · e59]

Obesity

Recommendation Grade
Lifestyle first: 5–10% weight loss (calorie restriction + activity); yearly counselling; multicomponent behavioural programmes 1, A
Non-judgemental approach; long-term maintenance programmes 1, B-NR
Stage 1 (BMI ≥27): GLP-1-based therapy with structured lifestyle 2a, A
Metabolic and bariatric surgery for stages 1–3 not responding 2a, A
Stage 4 with ASCVD, BMI ≥27: GLP-1-based therapy with proven CV benefit 1, B-R
Stage 4 with ASCVD: naltrexone–bupropion or phentermine are harmful (raise BP and HR) 3: Harm, B-R
Obesity with symptomatic HFpEF: GLP-1-based therapy 1, A
GLP-1 therapy: reassess at 3–6 months; <5% weight loss = poor response 1, B-NR

Adapted from AHA/ACC/ADA/ASN 2026 [e75–e118]

Type 2 diabetes

  • Stages 2–3: lifestyle plus intensified multifactorial treatment of glucose, BP, lipids and albuminuria. [1, A; 1, B-R · e83]
  • PREVENT-CVD ≥7.5%: SGLT2i or GLP-1-based therapy with proven benefit. [1, A · e83]
  • Metformin if HbA1c is 0.5–1% above goal on cardioprotective drugs. [2a, A · e83]
  • Stage 4 with ASCVD: SGLT2i or GLP-1-based therapy; the combination can help. [1, A; 2a, C-LD · e100]
  • Stage 4 with HF: SGLT2i first line; add GLP-1-based therapy in HFpEF. [1, A; 2a, B-R · e105–e106]
  • After gestational diabetes: OGTT at 4–12 weeks postpartum; lifestyle or metformin if prediabetic. [1, B-R · e82]

CKD

flowchart TD
    A["CKM stage 2–3 with CKD"] --> R["RASi at maximum tolerated dose<br/>T2D, or no T2D with UACR ≥30 · eGFR ≥30<br/>Class 1"]
    A --> S["SGLT2i<br/>T2D, or no T2D with UACR ≥200 · eGFR ≥20<br/>Class 1 (UACR 30–199 without T2D: 2a)"]
    R --> F{"T2D and UACR ≥30<br/>despite RASi + SGLT2i?"}
    S --> F
    F -->|"eGFR ≥25"| N["Add finerenone (nsMRA)<br/>Class 1"]
    F -->|"UACR ≥100"| G["Add GLP-1-based therapy with<br/>proven kidney and CV benefit<br/>Class 1"]
Built from AHA/ACC/ADA/ASN 2026 CKD recommendations [e88]; see Figures 9–11 in the guideline.

  • Recheck UACR 3–6 months after starting kidney-protective therapy; eGFR and potassium at 2–4 weeks after a RASi or MRA. [2a, B-R · e119]
  • CKD with HFrEF: ARNI (or another RASi) if eGFR ≥30; SGLT2i for HF of any EF if eGFR ≥20. [1, A · e108]

Pre-HF and subclinical atherosclerosis

Situation Recommendation Grade
Pre-HF Intensive lifestyle and risk-factor control 1, B-R
Pre-HF with T2D or CKD SGLT2i first line 1, B-NR
+ diabetes, CKD, UACR ≥100 Add GLP-1-based therapy 2a, B-NR
+ diabetes, CKD, UACR ≥30 Add finerenone 2a, B-NR
CAC >100 Start or intensify preventive therapy 2a, B-NR

Adapted from AHA/ACC/ADA/ASN 2026 [e93]

Liver, sleep and pregnancy

  • MASLD: FIB-4 every 1–2 years with diabetes or ≥2 risk factors (every 2–3 years with prediabetes). GLP-1-based therapy for MASLD with T2D, or MASH with significant fibrosis. [1, B-NR; 1, B-R · e113]
  • Sleep apnoea: screen yearly with obesity; treat with weight management plus CPAP. [2a; 1, B-R · e115–e116]
  • Pregnancy: HbA1c <6.5% before conception with diabetes; after an adverse pregnancy outcome (pre-eclampsia, gestational diabetes etc.), screen CKM risk factors within the first postpartum year and move to long-term primary care. [1 · e117]

Clinical pearls

  • CKM stages 0–4: adiposity → metabolic risk or CKD → subclinical CVD → clinical CVD.
  • Asian cut-offs: BMI ≥23, waist ≥80/90 cm.
  • Stage 3 risk equivalents: CKD G4–G5 or PREVENT-CVD ≥20%.
  • Kidney sequence: RASi → SGLT2i → finerenone → GLP-1 RA.
  • Avoid naltrexone–bupropion and phentermine with established ASCVD.

Classes and levels of evidence

How AHA/ACC/ADA/ASN 2026 grades its recommendations. Adapted from AHA/ACC/ADA/ASN 2026 Table 2 [e55]. Hover over any class or level cited on this page to see what it means.

Class Strength Meaning Wording used
Class 1 Strong Benefit >>> risk is recommended; is indicated, useful, effective or beneficial; should be performed or administered
Class 2a Moderate Benefit >> risk is reasonable; can be useful, effective or beneficial
Class 2b Weak Benefit ≥ risk may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain
Class 3: No benefit Moderate Benefit = risk (generally used only with level A or B) is not recommended; is not indicated, useful or effective; should not be performed or administered
Class 3: Harm Strong Risk > benefit potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered
Level Meaning
Level A High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies
Level B-R (randomised) Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs
Level B-NR (non-randomised) Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies
Level C-LD (limited data) Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans
Level C-EO (expert opinion) Consensus of expert opinion based on clinical experience

Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.